[{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alnylam Presents New Data for Zilebesiran, an Investigational RNAi Therapeutic for the Treatment of Hypertension, at the American Heart Association Scientific Sessions 2021","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$310.0 million","newsHeadline":"Roche Enters Partnership with Alnylam to Co-Develop and Co-Commercialise RNAi Therapeutic Zilebesiran to Treat Hypertension in Patients with High Cardiovascular Risk","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Chugai In-Licenses RNAi Therapeutic Zilebesiran for Hypertension with High Cardiovascular Risk","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Alnylam Pharmaceuticals","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche and Alnylam Report Positive Topline Results from Phase 2 Study Kardia-1 of Zilebesiran, an Investigational RNAi Therapeutic in Development to Treat Hypertension in Patients at High Risk of Cardiovascular Disease","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"SWITZERLAND","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Roche and Alnylam Report Positive Topline Results from The Phase II Kardia-2 Study in People with Hypertension, Demonstrating Clinically Significant Blood Pressure Reductions with Zilebesiran when Added to Standard of Care","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2024","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Phase II\/ Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II\/ Phase III"}]
Find Clinical Drug Pipeline Developments & Deals for Zilebesiran
Under the license agreement between Roche and Chugai, Chugai obtained commercialization rights in Japan for ALN-AGT01 (zilebesiran), an RNAi therapeutic targeting angiotensinogen, for hypertension with high cardiovascular risk.
ALN-AGT01 (zilebesiran) investigational, subcutaneously administered RNAi therapeutic targeting angiotensinogen in development for the treatment of hypertension in high unmet need populations.
ALN-AGT01 (zilebesiran) is an investigational, subcutaneously administered RNAi therapeutic targeting angiotensinogen. It is being evaluated in combination with standard of care for the treatment of hypertension.
ALN-AGT01 (zilebesiran), is an investigational, subcutaneously administered RNAi therapeutic targeting angiotensinogen (AGT) in development for the treatment of hypertension in high unmet need populations.
Under the partnership, Roche and Alnylam will co-develop and co-commercialise RNAi therapeutic ALN-AGT01 (zilebesiran), an investigational RNAi therapeutic currently in Phase 2 for the treat hypertension in patients with high cardiovascular risk.
Across various cohorts in the Phase 1 study, zilebesiran was shown to be generally well tolerated with an acceptable safety profile that supports continued development.
Market Place
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
